Skip to main content

Table 1 Data of 447 melanoma patients from TCGA

From: UTRN inhibits melanoma growth by suppressing p38 and JNK/c-Jun signaling pathways

Characteristics

N

Percentages

Characteristics

N

Percentages

T

Clark level

 Ti

7

1.75

 I/II/III

98

31.72

 T1

41

10.28

 IV/V

211

68.29

 T2

76

19.05

Ulceration

 T3

89

22.31

 No

144

47.37

 T4

144

36.09

 Yes

160

52.63

N

Cancer status

 N0

222

59.04

 Tumor free

210

49.64

 N1

73

19.41

 With tumor

213

50.35

 N2

49

13.03

New tumor event

M

 No

110

25.23

 M0

402

95.04

 Yes

326

74.77

 M1

21

4.96

Race

Stage

 Asian

11

2.51

 Stage0

6

1.49

 White

427

97.49

 Stage1

76

18.81

Age

 Stage2

133

32.92

 < 60

237

53.02

 Stage3

169

41.83

 ≥ 60

210

46.98

 Stage4

20

4.95

Site

 Extremities

191

49.35

 Head and neck

32

8.27

 Trunk

164

42.38

  1. Patient characteristics included TNM stage, clinical stage, Clark level, ulceration, cancer status, new tumor event, race, age and site were identified